The duodenal-jejunal bypass liner prevents the interaction of food with enzymes and hormones in the proximal intestine to treat type 2 diabetes and obesity.
This prevents the partially digested food from entering the first and initial part of the secondary stage of the small intestine, mimicking the effects of the biliopancreatic portion of Roux en-Y gastric bypass (RYGB) surgery.
[2][3][4] Initial clinical research by Rubino et al. in 2006 produced two hypotheses for why duodenal-jejunal bypass is effective in improving glucose homeostasis.
Their "hindgut hypothesis" claims that by expediting the delivery of chyme to the distal intestine, the secretion of the gut hormone GLP-1 and glucose-dependent insulin is more effectively promoted, improving glucose metabolism.
The "foregut hypothesis," on the other hand, states that by bypassing the duodenum and proximal jejunum (the initial parts of the small intestine), the inhibiting hormone GIP is secreted less, resulting in improved glucose tolerance.